Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30,...
Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017
Emergent BioSolutions (NYSE:EBS) will release its financial results for the third quarter and nine months of 2017 immediately after market close on Thursday, November 2,...
Emergent BioSolutions Completes Acquisition of ACAM2000® Business From Sanofi
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Sanofi’s ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) business, which includes ACAM2000, the only...
Emergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Supply Nerve Agent Antidote Auto-Injector
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at up to approximately $25 million by the U.S. Department of State to supply TROBIGARD™ (Atropine...
Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of raxibacumab, a fully human monoclonal antibody approved by the U.S. Food and Drug Administration (FDA)...
Emergent BioSolutions Announces Closing of New $200 Million Senior Secured Credit Facility
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed a new five-year, $200 million syndicated senior secured credit facility....
Emergent BioSolutions to Supply DoD With Chemical Threat Countermeasure RSDL Under Five-Year Follow-On Contract Valued at Up to $171 Million
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a five-year follow-on contract valued at up to approximately $171 million by the...
Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at approximately $63 million by the Biomedical Advanced Research and Development Authority (BARDA) to...
Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and six months ended June 30,...
Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded approximately $23 million to develop a novel multi-drug auto-injector for nerve agent antidote...
Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine Technology
Emergent BioSolutions Inc. (NYSE:EBS) today announced a licensing agreement with Valneva SE for global exclusive rights to Valneva’s Zika vaccine technology,...
Emergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August 3, 2017
Emergent BioSolutions Inc. (NYSE:EBS) will release its second quarter financial results immediately after market close on Thursday, August 3, 2017....